![Martin Babler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Babler
Directeur Général chez
ALUMIS INC.
Fortune : 2 M $ au 31/05/2026
Profil
Mr. Martin Babler is a Chairman, President & Chief Executive Officer at Alumis, Inc., an Independent Director at Prelude Therapeutics, Inc., an Independent Director at Omega Alpha SPAC and a Director-Emerging Companies Section at Biotechnology Innovation Organization.
He is on the Board of Directors at Prelude Therapeutics, Inc., Omega Alpha SPAC and Sardona Therapeutics, Inc. Mr. Babler was previously employed as an Independent Director by 89bio, Inc., an Independent Director by Neoleukin Therapeutics, Inc., an Independent Director by ZS Pharma, Inc., a President, Chief Executive Officer & Director by Principia Biopharma, Inc., an Independent Director by Infinity Pharmaceuticals, Inc., a President & Chief Executive Officer by Talima Therapeutics, Inc., a Vice President-Immunology Sales & Marketing by Genentech, Inc., and a Principal by Eli Lilly & Co.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALUMIS INC. 0,09 % | 05/05/2026 | 110 491 ( 0,09 % ) | 2 M $ | 31/05/2026 |
| 09/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Martin Babler
| Sociétés | Poste | Début |
|---|---|---|
| OMEGA ALPHA SPAC | Directeur/Membre du Conseil | 01/09/2020 |
| PRELUDE THERAPEUTICS INCORPORATED | Directeur/Membre du Conseil | 19/07/2021 |
| ALUMIS INC. | Directeur Général | 23/09/2021 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Corporate Officer/Principal | - |
Sardona Therapeutics, Inc.
 Sardona Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides cancer therapy services | Directeur/Membre du Conseil | - |
Anciens postes connus de Martin Babler
| Sociétés | Poste | Fin |
|---|---|---|
| 89BIO, INC. | Directeur/Membre du Conseil | 30/10/2025 |
| PRINCIPIA BIOPHARMA INC. | Directeur Général | 01/11/2020 |
| ZS PHARMA INC | Directeur/Membre du Conseil | 17/12/2015 |
| INFINITY PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/03/2014 |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
74
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Talima Therapeutics, Inc.
 Talima Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drug delivery systems | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
ZS Pharma, Inc.
 ZS Pharma, Inc. BiotechnologyHealth Technology Develops develop new treatments of kidney and liver diseases | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a R&D driven and AI-powered biopharma company | Health Technology |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
89bio, Inc.
 89bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
Omega Alpha SPAC
 Omega Alpha SPAC Financial ConglomeratesFinance Operates as a blank check company | Finance |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Sardona Therapeutics, Inc.
Sardona Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides cancer therapy services | Health Services |
